Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationa... Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of August 9, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.
Disclosures of Vifor Pharma
Explore Vifor Pharma's complete collection of publicly available corporate disclosures, including annual
reports, sustainability reports, financial statements, ESG data spreadsheets, and related web
publications. Each document is sourced directly from Vifor Pharma's official channels and fully
traceable to its official company sources.
The table below lists all of Vifor Pharma's' corporate disclosure by name and reporting period, ensuring
full transparency and easy access.
If you want to search across Vifor Pharma's' disclosures for specific data or insights, use our Disclosure Search.
Name
Reporting Period
Annual Report
2021
Corporate Governance Report
2021
Financial Report
2021
Responsibility Report
2021
Responsibility Report
2020
GRI index
2020
Annual Report
2020
Responsibility Report
2019
Annual Report
2019
Responsibility Report
2018
Annual Report
2018
Responsibility Report
2017
Annual Report
2017
Annual Report
2016
Annual Report
2015
Annual Report
2014
Annual Report
2013
Real-Time Disclosures Datafeed
Get Notified Within Seconds of New Corporate Disclosures
Tracenable is building a high-speed disclosure monitoring system that delivers instant alerts when companies
publish new reports or data. Could a real-time datafeed (via SFTP, RSS or API) enhance your investment or
analytical workflows?